



Article

Nerve Growth Factor, Antimicrobial Peptides and Chemotherapy: Glioblastoma Combination Therapy to Improve Their Efficacy

Alexandr Chernov ^{1,*}, Igor Kudryavtsev ¹, Aleksei Komlev ¹, Diana Alaverdian ², Anna Tsapieva ¹ ,
Elvira Galimova ^{1,3,*} and Olga Shamova ^{1,4}

¹ Institute of Experimental Medicine, WCRC “Center for Personalized Medicine”, Saint-Petersburg 197022, Russia; igorek1981@yandex.ru (I.K.); komlev1420@yandex.ru (A.K.); anna.tsapieva@gmail.com (A.T.); oshamova@yandex.ru (O.S.)

² Medical Genetics, Department of Medical Biotechnologies, University of Siena, 53100 Siena, Italy; diana.alaverdian@dbm.unisi.it

³ Sechenov Institute of Evolutionary Physiology and Biochemistry, Russian Academy of Sciences, Saint-Petersburg 194223, Russia

⁴ Department of Biochemistry, Saint Petersburg State University, Saint-Petersburg 199034, Russia

* Correspondence: alexanderchernov1981@gmail.com (A.C.); elvira8galimova@gmail.com (E.G.); Tel.: +7-(812)-234-68-68 (A.C. & E.G.)

Abstract: Glioblastoma (GBM) is an aggressive and lethal malignancy of the central nervous system with a median survival rate of 15 months. We investigated the combined anticancer effects of nerve growth factor (NGF), cathelicidin (LL-37), and protegrin-1 (PG-1) with chemotherapy (temozolomide, doxorubicin, carboplatin, cisplatin, and etoposide) in the glioblastoma U251 cell line to overcome the limitations of conventional chemotherapy and to guarantee specific treatments to succeed. The MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay was used to study cell viability and to determine the cytotoxic effects of NGF, LL-37, and PG-1 and their combination with chemotherapy in U251 cells. Synergism or antagonism was determined using the combination index (CI) method. Caspase-3 activity was evaluated spectrophotometrically using a caspase-3 activity assay kit. Apoptosis was analyzed with flow cytometry using propidium iodide (PI) and YO-PRO-1. NGF and the peptides showed a strong cytotoxic effect on U251 glioma cells in the MTT test (IC₅₀ 0.0214, 3.1, and 26.1 μM, respectively) compared to chemotherapy. The combination of PG-1 + etoposide had a synergistic effect on apoptosis of U251 glioma cells. It should be noted that the cells were in the early and late stages of apoptosis, respectively, compared with the control cells. The caspase-3 activation analysis revealed that the caspase-3 level was not significantly ($p > 0.05$) increased in U251 cells following PG-1 with etoposide treatment compared with that in the untreated cells, suggesting that the combination of PG-1 and etoposide may induce caspase-independent apoptosis in U251 cells. NGF, LL-37, and PG-1 represent promising drug candidates as the treatment regimen for GBM. Furthermore, the synergistic efficacy of the combined protocol using PG-1 and etoposide may overcome some of the typical limitations of the conventional therapeutic protocols, thus representing a promising approach for GBM therapy.

Keywords: glioblastoma; nerve growth factor; antimicrobial peptides; chemotherapy; synergistic effect



Citation: Chernov, A.; Kudryavtsev, I.; Komlev, A.; Alaverdian, D.; Tsapieva, A.; Galimova, E.; Shamova, O. Nerve Growth Factor, Antimicrobial Peptides and Chemotherapy: Glioblastoma Combination Therapy to Improve Their Efficacy. *Biomedicines* **2023**, *11*, 3009. <https://doi.org/10.3390/biomedicines11113009>

Academic Editor: Pasquale De Bonis

Received: 11 September 2023

Revised: 7 October 2023

Accepted: 24 October 2023

Published: 9 November 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

GBM is the most malignant brain tumor with high mortality in adults [1]. According to the International Agency for Research on Cancer (Globocan), the incidence of brain tumors was assessed in 308,102 cases in 2020 [2]. The incidence of GBM in Caucasians compared to other populations is 2.0 times higher, and in males compared to females, 1.6 times higher.

The treatment for GBM includes maximal safe surgical resection followed by radiation therapy and chemotherapy [3] with the recent addition of tumor-treating fields (TTFields) [4]. Despite the combined modality treatment with surgery, radiotherapy, and chemotherapy, the improvement of the survival rate of glioma patients is still limited. The median survival time for patients is only approximately 15 months, and the 2-year survival rate is only 26.5% [5]. Moreover, the disease rapidly progresses and leads to relapse at 8–9 months post diagnosis [6]. Recent studies demonstrate that tumor heterogeneity with mixtures of genetically distinct subclones may contribute to drug resistance and disease relapse [7–9]. Therefore, new and effective therapeutic methods for the successful treatment of GBM are desperately needed.

In addition to ongoing estimations of novel immune-, viro-, and geno-therapies, recent studies of the genome, epigenome, transcriptome, proteome, and metabolome within GBM cancer cells have identified several potential biomarkers and therapeutic targets, including cell cycle and DNA damage repair pathways, angiogenesis inhibitors, and inhibitors of signaling [10–12]. Numerous studies demonstrate that NGF and cationic antimicrobial peptides (AMPs) possess significant therapeutic potential and can be considered as candidates for the next generation of anticancer drugs [13,14].

NGF is the first discovered and best characterized member of the neurotrophins (NTs) family, essential for the survival, differentiation, and functional activity of peripheral sensory and sympathetic nerve cells [15,16]. Via the initiation of precursor cells and other growth factors, NGF supports the repair of neurons damaged by ischemia, inflammation, or trauma [17,18]. The evidence obtained from in vitro and in vivo studies shows that NGF inhibits cancer cell proliferation or mitogenesis [19–24]. Topical ocular NGF administration is safe and effective, reducing glioma in vivo and the progression of pediatric optic glioma [25–28]. Further studies might be necessary to elaborate novel in vitro and in vivo techniques to verify the antitumoral activities of NGF.

AMPs, also known as host defense peptides, are part of the innate immune response found in a wide variety of life forms from microorganisms to humans. To date, more than 5000 AMPs have been discovered or synthesized [29]. In vitro studies demonstrate that AMPs possess biological activities towards bacteria, fungi, and some viruses, interacting with negatively charged lipids on cell membranes through electrostatic interactions [29–32]. In addition to antibacterial activities, AMPs have anticancer activities, suggesting a new strategy for cancer therapy [33–35]. The electrostatic interactions between cancer cells and AMPs are crucial for selective binding with cancer cell membranes and selective connection with ion channels [33–35]. AMPs are an effective alternative to conventional chemotherapeutics with a low propensity to elicit the development of drug resistance as well as to display toxicity to healthy cells [36–39]. The AMPs, on the basis of their activities, are divided into those that are toxic to bacteria and cancer cells but not lethal to normal mammalian cells and those that are toxic to bacteria, cancer cells as well as normal mammalian cells [32,40]. The antimicrobial peptides LL-37 and PG-1 are toxic to normal mammalian cells [29,40].

Combination treatments delay the development of drug resistance and reduce the dosage of individual drugs, thereby minimizing side effects [41,42]. Studies on the combinatorial effects of antimicrobial peptides, especially on U251 glioma cells, are missing.

In this study we examine the effects induced by NGF, LL-37, and PG-1 and their potential antitumor activity in the U251 cell line. Moreover, another objective is to investigate the synergistic effect of NGF, LL-37, and PG-1 to find out the most effective anticancer treatment combination. This study serves as an initial attempt to assess the combination effects of NGF, LL-37, and PG-1 with other standard chemotherapies.

2. Materials and Methods

2.1. Pharmacological Agents, Chemicals, Peptides, and Reagents

Cathelicidin LL-37 was produced via the Fmoc solid phase synthetic approach on a Symphony X peptide synthesizer (Protein Technologies, Tucson, AZ, USA), using standard

synthesis protocols. The porcine protegrin-1 PG-1 (SynPep Corporation, Dublin, CA, USA) was kindly provided to us by Prof. R. Lehrer (University of California, Los Angeles, CA, USA). Nerve Growth Factor β Human (Sigma-Aldrich, Saint Louis, MO, USA), gentamicin sulfate (40 mg/mL solution, Shandong Weifang Pharmaceutical Factory Co., Ltd., Shandong, China), Doxorubicin-lans[®] (intravascular and intravesical solution, 2 mg/mL, vials 10 mg, Veropharm, Russia), Carboplatin-lans[®] (concentrate for solution for infusion, 10 mg/mL, vials, 50 mg/5 mL, Veropharm, Russia), Temozolomide (temodal[®] Capsules, 100 mg, Orion Corporation, Tengstrominkatu 8, FIN-20360 Turku, Finland), Cisplatin-lans[®] (concentrate solution for infusion, 0.5 mg/mL, vials 25 mg/50 mL, Veropharm, Russia), and Etoposide "Ebewe" (concentrate for solution for infusion, 20 mg/mL, 10 mL, Ebewe Pharma, Ges.m.b.H.Nfg.KG, Unterach am Attersee, Austria) were also used.

2.2. Cell Culture

The human glioma cell line U251 was obtained from the Institute of Cytology of the Russian Academy of Sciences (St. Petersburg, Russia) and was authenticated with the short tandem repeat assay. The cell culture was cultured in Dulbecco's modified Eagle medium (DMEM, Sigma-Aldrich, Saint Louis, MO, USA, catalog No. D5796) supplemented with 10% fetal bovine serum (Sigma-Aldrich, Saint Louis, MO, USA, catalog No. F2442) and gentamicin sulfate 10^{-4} g/mL (Shandong Weifang Pharmaceutical Factory Co., Ltd., Shandong, China). The cell culture was maintained under a humid condition of 5% CO₂ and 95% air at 37 °C [43,44]. An ethics approval for this study was obtained from the Local Ethics Committee at the Institute of Experimental Medicine, Saint-Petersburg on 21 October 2020 (No. 6/20).

2.3. Concentrations of Compounds

The U251 cells were treated with NGF at concentrations of 0.23, 0.37, 0.94, 1.88, 3.7, and 7.5 nM; with PG-1 at concentrations of 2, 4, 8, 16, 32, and 64 μ M; and with LL-37 at concentrations of 0.5, 1, 2, 4, 8, and 16 μ M for the MTT. We used and compared the IC₅₀ of NGF, LL-37, and PG-1 with the IC₅₀ of the chemotherapy drugs doxorubicin, carboplatin, temozolomide, cisplatin, and etoposide on human U251 glioma cells. Cisplatin was tested at concentrations of 1.66 mM, and 830, 332, 166, 83, and 3.32 μ M; carboplatin was tested at concentrations of 26.9, 2.69, and 1.35 mM, and 673, 269, and 134 μ M; temozolomide was tested at concentrations of 15.5, 5.15, and 1.55 mM, and 770, 386, and 155 μ M; doxorubicin was tested at concentrations of 920, 460, 73.6, 36.8, 18.4, and 7.36 μ M; and etoposide was tested at concentrations of 27, 13.5, 6.79, 3.39, 1.69, and 0.85 μ M. Accordingly, we used NGF at 3.7 nM, LL-37 at 2 and 3 μ M, and PG-1 at 4 and 8 μ M concentrations in both the trypan blue exclusion and MTT assays, respectively.

We determined the cytotoxicity index (CI) by using the untreated cells as a negative control. The percentage of cytotoxicity N (%) was calculated with the following Equation (1):

$$N(\%) = \left(\frac{1 - \text{sample}}{\text{control}} \right) \times 100 \quad (1)$$

where N% is the CI of the reagents; sample is the cell survival rate treated with chemotherapeutic agents, NGF, LL-37, and PG-1, as well as NGF, LL-37, PG-1, and chemotherapy combinations; and control is the cell survival rate in the control [45].

2.4. MTT Assay

We used the MTT assay to evaluate the effects of NGF, LL-37, PG-1, temozolomide, doxorubicin, carboplatin, cisplatin, and etoposide toward the U251 cells [46,47]. U251 glioma cells were seeded in a 96-well plate at 10,000 cells/well and incubated for 24 h at 37 °C with 5% CO₂. The cells were treated with different chemotherapy drugs and peptides in various concentrations and incubated for a further 24 h. Briefly, 2-fold serial dilutions of NGF, PG-1, LL-37, and 2-fold to 10-fold serial dilutions of the chemotherapy drugs were added to glioma U251 cells in a 96-well cell culture plate. Each assay was

performed at least three times and is represented as the mean of the different experiments. The negative controls (0% cell survival) were made with 100 μ L of the DMEM, whereas the positive controls were set up with U251 cells + 50 μ L of DMEM. A total of 25 μ L MTT (5 mg/mL) was added. Subsequently, the MTT (Thiazolyl blue tetrazolium bromide) solution (25 μ L, 5 mg/mL) was added to each well, and incubation was allowed to continue for a further 3 h. The absorbance of formazan in each well was measured at 570 nm and 690 nm for reference using a plate reader (Molecular Devices, San Jose, CA, USA).

The percentage (%) of survival cells could be defined with Equation (2) [48]:

$$\text{Survival}(\%) = \frac{\text{OD sample} - \text{OD 0\% survival}}{\text{OD 100\% survival} - \text{OD 0\% survival}} \times 100\% \quad (2)$$

where OD sample, OD 0% survival, and OD 100% survival are the values for the test sample, negative control (0% cell survival), and positive control (100% cell survival), respectively.

2.5. Assessment of Drug-Concentration Effect and Calculation of the Combination Index

The cytotoxicity results are expressed as the IC₅₀, the half-maximal (50%) inhibitory concentration of NGF, PG-1, LL-37, and the chemotherapy drugs. The IC₅₀ was calculated using the OriginPro 8.5.1. Software (OriginLab, Northampton, MA, USA) with nonlinear curve fitting. The IC₅₀ values presented ($\pm$ standard deviation) are the average values obtained from three independent experiments. We calculate the IC₅₀ for the combination of NGF, PG-1, LL-37 and the chemotherapy drugs using the Formula (3):

$$\text{IC}_{50} \text{ chemotherapy} = \text{IC}_{50} \text{ combination} \times W \quad (3)$$

where W is the proportion of the chemotherapy drugs in the combination.

The cells were treated with a combination of NGF, PG-1, LL-37, and the chemotherapy drugs to calculate the combination index (CI) according to the Chou–Talalay method [49], using the CompuSyn 2.0 software (ComboSyn, Inc., Paramus, NJ, USA). The CI was evaluated with the Equation (4):

$$\text{CI} = \frac{(D)_1}{(D_x)_1} + \frac{(D)_2}{(D_x)_2} \quad (4)$$

where (D_x)₁ и (D_x)₂ are the doses of substances 1 and 2 used in combination to achieve x% drug effect. D₁ and D₂ are the doses for single compounds to achieve the same effect. CIs were determined using the unified theory in various doses and mixing ratios (slight synergy CI < 0.85–0.9; moderate synergy CI = 0.7–0.85; synergy CI = 0.3–0.7; strong synergy CI = 0.1–0.3; very strong synergy CI < 0.1; slight antagonism CI < 1.1–1.2; moderate antagonism CI = 1.2–1.45; antagonism CI = 1.45–3.3; strong antagonism CI = 3.3–10; very strong antagonism CI > 10; additivity 0.9 < CI < 1.1).

2.6. Assessment of Cell Viability with Flow Cytometry Using YO-PRO-1 and PI

The effects of NGF, PG-1, LL-37, and the chemotherapy drugs on the apoptosis/necrosis of U251 cells were analyzed using flow cytometry. U251 cells at a density of 1×10^6 cells/well were seeded into 6-well plates, incubated for 24 h at 37 °C, and then centrifuged at $1000 \times g$ for 10 min. Cell viability and cell death machinery were assessed by flow cytometry using YO-PRO-1 vs. PI staining, as it was described in details previously [50,51]. The cells were re-suspended in 200 μ L $1 \times$ in PBS, and 5 μ L YO-PRO-1 and 2.5 μ L PI (Sigma-Aldrich, USA, final concentration of PI 1 μ g/mL) were added to 100 μ L of cell suspension and incubated for 15 min at 37 °C in the dark. The uptake of the dyes was assessed with flow cytometry using a Navios™ flow cytometer (Beckman Coulter, Indianapolis, IN, USA) and Kaluza™ analysis software version 1.2 (Beckman Coulter, Indianapolis, IN, USA).

2.7. Caspase Activation Analysis

Caspase-3 activity was evaluated with the «Caspase 3 Assay Kit, Colorimetric» (Sigma, Saint Louis, MO, USA) according to the manufacturer's protocol [52]. The Caspase 3 Colorimetric Assay Kit is based on the hydrolysis of acetyl-Asp-Glu-Val-Asp p-nitroanilide (Ac-DEVD-pNA) through caspase-3, causing the release of the p-nitroaniline (pNA) moiety. Human glioma U251 cells (5.5×10^6 cells/mL) were plated into 6-well plates and treated with 10 μ L etoposide, PG-1, and their combination for 3 h or PBS for the control. Then, the cells were collected and centrifuged for 5 min (4 °C, $600 \times g$), re-suspended, and incubated in the lysis buffer on ice for 30 min. The specimens were centrifuged for 20 min (4 °C, $10,000 \times g$). The final 100 μ L reaction mixture, including 40 μ L assay buffer, 50 μ L cell lysate supernatant, and the 10 μ L Caspase-3 substrate Ac-DEVD-pNA (2 mM), were incubated at 37 °C for 18 h. Caspase-3 activity was assessed at 405 nm using the Multiscan Microplate Readers (ThermoFisher, Waltham, MA, USA).

2.8. Statistical Analysis

The experiments were performed at least three times. The Student's t-test was used to determine the statistical significance of the differences between the means of the different treatments and their respective control groups. The data were calculated with the standard deviation and considered significant at $p < 0.05$. The differences between two independent groups with a small number of samples ($n < 30$) were compared with the nonparametric Mann–Whitney U-test [53]. The descriptive statistics were carried out with the GraphPad Prism software, version 8.01, for Windows (GraphPad Software, La Jolla, CA, USA).

3. Results

3.1. Sensitivity of U251GBM Cells to NGF, LL-37, PG-1, and Chemotherapy and IC50 Calculation

For determining the cytotoxic effects of NGF, LL-37, PG-1, and chemotherapy, the MTT assay was performed using the U251 cell line. The results showed that the U251 cells were sensitive to treatment in a dose-dependent manner. The dose–response curves are shown in Figure 1. The IC50 values for the NGF, LL-37, PG-1, and chemotherapeutic agents were established. The IC50 values of the tested agents toward the U251 cells are presented in Table 1. The determination of the IC50 for NGF, LL-37, and PG-1 and the IC50 for the anticancer chemotherapeutic agents showed that NGF and the peptides have a strong cytotoxic effect on the U251 glioma cells in the MTT ($IC_{50} = 2.14 \times 10^{-9}$ M, 3.1, and 26.1 μ M, respectively) compared to chemotherapy (Table 1). We found that NGF was more effective than LL-37, PG-1, and chemotherapy in reducing the viability of the human glioblastoma U251 cells (Table 1). The data indicated that NGF had good in vitro activity against the U251 cells. According to the guidelines for preclinical drug testing, a compound of a new class is considered cytotoxic at $IC_{50} \leq 10^{-4}$ M if its $IC_{50} \leq IC_{50}$ of the reference substance [54]. In the U251 cells, the IC_{50} of LL-37, NGF, and PG-1 was significantly low than 10^{-4} M, thus demonstrating cytotoxic effects. Additionally, etoposide had a higher efficacy than the other chemotherapeutic agents. The results showed that etoposide inhibited the proliferation of glioma cells with IC_{50} values of 4.9 to 25.9 μ M.


Table 1. Cytotoxic activity of the combined treatment NGF, LL-37, and PG-1 with chemotherapy in glioma cells (IC_{50} : μ M). IC_{50} values (μ M) were obtained with the MTT test.

Compounds	N	Monotherapy, IC_{50} μ M	NGF + Chemotherapy, IC_{50} μ M	LL37 + Chemotherapy, IC_{50} μ M	PG1 + Chemotherapy, IC_{50} μ M
MTT test					
Doxorubicin	3	1554.98 ± 207.5	600.5 ± 55.75	5265.5 ± 1031.0	730.9 ± 12.43
Carboplatin	3	3652.9 ± 670.8	2880.6 ± 275.5	3513.3 ± 493.0	2938.9 ± 529.7
Temozolomide	3	1725.7 ± 494.0	$16,804.0 \pm 937.4$	4007.0 ± 365.5	9761.7 ± 997.0


Table 1. Cont.

Compounds	N	Monotherapy, IC ₅₀ μ M	NGF + Chemotherapy, IC ₅₀ μ M	LL37 + Chemotherapy, IC ₅₀ μ M	PG1 + Chemotherapy, IC ₅₀ μ M
Cisplatin	3	371.5 $\pm$ 23.50	207.4 $\pm$ 8.477	869 $\pm$ 107.5	237.9 $\pm$ 29.83
Etoposide	3	25.90 $\pm$ 0.61	13.7 $\pm$ 0.1129	17.9 $\pm$ 3.03	17.0 $\pm$ 1.80
NGF (nM)	3	2.14 $\pm$ 5.0			
LL-37	3	3.1 $\pm$ 0.4063			
PG-1	3	26.1 $\pm$ 7.6			

A



B



C




Figure 1. Cont.




Figure 1. Graph of viability versus drug concentration. Cell viability was assessed with the MTT assay. Dose-dependent effect of NGF (A), LL-37 (B), and PG-1 (C) and their combination with chemotherapy on cell viability at 24 h time-course. Data shown are representative of three separate experiments, and values are given as mean $\pm$ SD. Statistically significant difference * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$ combination effects from drug alone; # $p < 0.05$, ## $p < 0.01$, ### $p < 0.001$, #### $p < 0.0001$ —statistically significant difference drug or combination from control.

3.2. The Combination Index (CI) and Anti-Tumor Activity of Combined Treatment of NGF, LL-37, and PG-1 with Chemotherapy

We also examined the response of the U251 cell line to 15 different combinations of NGF, LL-37, PG-1, and chemotherapy. The cytotoxicity of the combined treatment of NGF, LL-37, and PG-1 with chemotherapy was measured with the MTT assay. The following drug combinations were used: NGF + chemotherapy (doxorubicin, carboplatin, temozolomide, cisplatin, etoposide), PG1 + chemotherapy (doxorubicin, carboplatin, temozolomide, cisplatin, etoposide), LL37 + chemotherapy (doxorubicin, carboplatin, temozolomide, cisplatin, etoposide), PG-1 + LL-37, PG-1 + NGF, and PG-1 + LL-37 + NGF.

The IC₅₀ values of all the combinations are shown in Table 1. After treatment for 24 h, the corresponding IC₅₀ values (measured using the MTT assay) of the PG-1 combinations with doxorubicin, carboplatin, cisplatin, and etoposide; NGF combinations with doxorubicin, carboplatin, cisplatin, and etoposide; and LL-37 combinations with cisplatin and etoposide were lower than that of the single-drug chemo treatment (Table 1). The data indicated that the presence of PG-1, NGF, and LL-37 could further promote the cytotoxicity of chemotherapeutic agents.

Further, the combinations of PG-1 with carboplatin, temozolomide, cisplatin, and etoposide and combination of NGF with cisplatin exhibited higher toxicity than that of the single-drug chemo treatment (Table 1). The CI values reflect the interaction between the two drugs. Synergism or antagonism was determined using the combination index method. The CI values of the tested agents toward the U251 cells are presented in Table 2. PG-1 combined with etoposide displayed synergistic effects with a CI value of 0.65 on the U251 glioma cells in the MTT, indicating that the combination of PG-1 with etoposide might also be promising.

Table 2. CI of the combined one-day exposure of NGF, LL-37, and PG-1 with chemotherapy on U251 glioma cells according to the MTT assay. The mean combination index (CI) value of combination treatments in U251 was calculated as explained in the Methods.

Compounds	PG1 + Chemotherapy	LL37 + Chemotherapy	NGF + Chemotherapy
MTT test			
Doxorubicin	0.94 additivity	188.6 very strong antagonism	2.42 antagonism
Carboplatin	1.46 antagonism	4.31 strong antagonism	2.69 antagonism
Temozolomide	6.04 strong antagonism	8.95 strong antagonism	9.73 strong antagonism
Cisplatin	1.38 antagonism	2.67 antagonism	2.78 antagonism
Etoposide	0.65 synergy	1.85 antagonism	2.34 antagonism

PG-1 combined with doxorubicin displayed an additive effect with a CI value of 0.94 in the U251 glioma cells with the MTT. Meanwhile, antagonism was found for the other combinations in the U251 cells.

The cytotoxic activities of all possible combinations of the three peptides, NGF, PG-1, and LL-37, were also analyzed on the U251 cultures using the MTT assay (Figure 2). The cytotoxic activity of the combinations of peptides PG-1 + LL-37, PG-1 + NGF, and PG-1 + LL-37 + NGF was significantly ($p < 0.05$) lower than that of PG-1 (Figure 2). The cytotoxic activity of the combinations PG-1 + LL-37, LL-37 + NGF, and PG-1 + LL-37 + NGF was significantly ($p < 0.05$) lower than that of LL-37 (Figure 2). The cytotoxic activity of the combinations PG-1 + NGF, LL-37 + NGF, and PG-1 + LL-37 + NGF was significantly ($p < 0.05$) lower than that of NGF (Figure 2).




Figure 2. Computed CI values for the combination of NGF on U251 human glioma cells according to the results of the MTT test (A); LL-37 with NGF and PG-1 on U251 human glioma cells according to the results of the MTT test (B); PG-1 with LL-37 and NGF on U251 human glioma cells according to the results of the MTT test (C). The results are presented as the means (columns) $\pm$ S.D. (bars) ($n = 3$, in triplicate). * $p < 0.05$, ** $p < 0.01$, **** $p < 0.0001$ statistically significant differences between CI value of drug or its combinations and control.

3.3. Cell Apoptosis Detected with Flow Cytometry

To verify the synergistic effects of PG-1 + etoposide on the U251 cells, the apoptotic effects of PG-1 + etoposide were tested using the YO-PRO-1 and PI apoptosis kit. The representative dot plots illustrating apoptotic status are shown in Figure 3. The percentage of apoptotic cells (early apoptotic plus late apoptotic cells) treated with the PG-1 + etoposide combination (Figure 3D) solution was $70.4 \pm 11.4\%$ (early apoptotic, $p < 0.0001$) and $11.7 \pm 4.7\%$ (late apoptotic, $p < 0.0054$), which was significantly higher in comparison with etoposide ($50.7 \pm 5.2\%$, $p < 0.0001$, $6.3 \pm 2.0\%$, $p > 0.05$) and PG-1 ($53.1 \pm 2.8\%$, $p < 0.0001$), respectively. Thus, the combination of PG-1 with etoposide has a synergistic cytotoxic effect in U251 glioma cells by increasing ($p < 0.0001$) the ratio of cells at the stage of early apoptosis compared to the action of etoposide and PG-1. These results indicated the potential synergistic enhancement of cancer therapy using PG-1 + etoposide.




Figure 3. Apoptosis, necrosis, and necroptosis analysis with flow cytometry using PI and YO-PRO-1. U251 cells were treated with etoposide (B) and PG-1 (C) individually and in combination (D) (etoposide + PG-1) for 24 h compared with that in the normal controls (A). C3 represents the rate of viable cells; C1 and C2 represent the rate of late apoptosis or necrosis; C4 represents the rate of early apoptosis.

3.4. Activation of Caspase-3 on U251 Cells

Caspase-3, one of the critical mediators of apoptosis, performs a key role in regulating both mitochondrial and death receptor apoptotic pathways. The activation of caspase-3 of the U251 cells was evaluated with the Caspase-3 Activity Assay Kit to confirm the probable pathways of the synergistic apoptotic effect of PG-1 + etoposide. The caspase-3 activation analysis demonstrated that the caspase-3 level was not significantly ($p > 0.05$) increased in the U251 cells following PG-1 + etoposide treatment compared with that in the untreated cells, suggesting that the combination of PG-1 and etoposide may induce caspase-independent apoptosis in U251 cells (Figure 4).




Figure 4. Caspase-3 activity of U251 cells; Data shown are representative of three separate experiments, and values are given as mean $\pm$ SD. * $p < 0.05$, statistically significant difference between control and PG-1.

4. Discussion

Our results showed that NGF, LL-37, and PG-1 were significantly cytotoxic to the U251 GBM cells compared to chemotherapy. We observed a dose-dependent cytotoxic effect with the NGF treatment. The higher doses of NGF (100–200 ng/mL) showed a cytotoxic effect to the U251 GBM cells, whereas low (10, 25, 50 ng/mL) concentrations of NGF induced a mitogenic effect. Previously, we also showed that NGF induced a strong cytotoxic effect on C6 glioma cells in the MTT test and xCELLigence real-time cell analysis [55]. The IC₅₀ values of the combinations of NGF with doxorubicin, carboplatin, and cisplatin were lower than the IC₅₀ values of the chemotherapy drugs alone in the MTT assay. These results indicate stronger cytotoxic antitumor effects of these combinations. Probably, the cytotoxic effects of NGF in glioma U251 cells may be related to its capacity to inhibit the basal oxygen consumption rate, ATP-synthetase, maximal respiration of mitochondria, and migration of these cells [56]. NGF, through interaction with its specific receptors, the p75 neurotrophin receptor (p75NTR) and the tropomyosin-related kinase A (TrkA), regulates carcinogenesis by either suppressing or supporting tumor growth. In vitro and in vivo data demonstrate that NGF inhibits cancer cell proliferation or mitogenesis [19–24].

However, other studies propose that NGF stimulates glioblastoma proliferation [50–52]. Giraud et al. presented evidence that detection of the p75NTR receptor in the Golgi apparatus could be correlated with a decrease in cell apoptosis that causes U-87 MG human glioblastoma cells to become tumorous [57]. NGF leads to clonal growth of the human glioblastoma cell line via binding of NGF to tyrosine kinase [58]. Singer et al. revealed that NGF, acting via Trk receptor phosphorylation, induced the growth of U251, U87, and U373 cells in culture by 9%, 16%, and 33%, respectively, compared with controls after 3 days [59]. Colocalizations of NGF with gamma-tubulin at the centrosomes throughout the cell cycle and phosphorylated TrkA with alpha-tubulin at the mitotic spindle were detected in a study of the direct mitogenic effects of NGF and TrkA in the glioma cell line U251 [23]. Modulation of the mitosis of human glioma cells by NGF is carried out through phosphorylation of TrkA and tubulin [59]. An analysis of NGF expression in astrocytoma samples from

70 adult patients revealed the overexpression of NGF in astrocytomas compared with that in the control cohort ($p < 0.05$), particularly in grade III ($p < 0.05$) [60]. An association of NGF overexpression in astrocytomas with the generation, location, progression, and pathological grade of the astrocytoma was detected [60]. Yang et al. demonstrated an overexpression of NGF and TrkA in U251 and distribution of NGF in the plasma and nuclei, while TrkA was distributed in the membrane and nucleoli [61]. Johnston et al. found that the expression of p75NTP significantly induced the migration and invasion of genetically distinct glioma cells [62]. In total, inconsistent results in the studies regarding the effects of NGF on U251 glioma cells can be due to the pleiotropic effects and colocalization of TrkA and p75NTR receptors and receptor complexes formation. Interaction of p75NTR with TrkA increased the affinity and selectivity of NGF binding, promoting TrkA signaling, supporting survival, and inducing differentiation of sympathetic neurons [63].

In the current study, we show that the IC₅₀ of the combination of LL-37 with etoposide was lower than the IC₅₀ of the chemotherapy drug alone, while the IC₅₀ of the combinations of LL-37 with temozolomide, cisplatin, carboplatin, and doxorubicin was higher than the IC₅₀ of the chemotherapy drugs. However, the combination of LL-37 with cisplatin in several doses (830, 332, 166, 83, 3.32 μ M) and the combination of LL-37 with carboplatin at 2.69 mM had a more cytotoxic effect than the chemotherapy drugs alone. We have recently detected that the cytotoxic effects of LL-37 with temozolomide in glioma U251 cells can be associated with their capacity to inhibit clonogenicity, migration, basal oxygen consumption rate, ATP-synthetase, and maximal respiration of mitochondria in these cells [56].

LL-37 induces tissue-specific or cell-specific effects by interacting with different membrane receptors in various cancer cells. Multiple mechanisms were discovered in lung, breast, gastric, and colon cancers by extensive LL-37 studies [64]. It was found that LL-37 plays a dual role in carcinogenesis, exerting pro- and anti-tumorigenic effects in different cancers [65]. LL-37 regulates tumorigenesis by either suppressing the growth of acute myeloid [66], lymphocytic leukemia [67], and gastric cancer [68] or supporting the growth of breast [69], ovarian [70], and lung cancers [71]. A study investigating LL-37 expression and function in colon cancer showed LL-37 downregulation in colon cancer tissues through the caspase-independent apoptotic pathway [72]. A comparative analysis of the effect of human LL37 and cationic peptides encoded by different viruses on the survival of human U87G glioblastoma cells revealed that LL-37 as well as LL17–32 inhibit the viability of U87G cells in a dose-dependent manner [73]. Whereas U87G is a highly radio-resistant GMB cell line, Colle et al. concluded that LL-37 and LL17–32 may be helpful in the therapy of glioblastomas [73]. An expression analysis of 84 genes related to DNA damage in wild-type and LL-37-knockdown melanoma cells (A375) and in breast cancer (SKBR3) established the downregulation of genes related to stemness, including telomerase reverse transcriptase, forkhead box D3, and undifferentiated embryonic cell transcription factor 1 [74]. Thus, LL37 regulates cancer cell stemness, potentially promoting a high resistance to radiation and chemotherapy.

The IC₅₀ of the combinations of PG-1 with doxorubicin, carboplatin, cisplatin, and etoposide was lower than the IC₅₀ of the chemotherapy drugs alone, which indicates higher cytotoxic effects of these combinations in glioma U251 cells compared with those of the chemotherapy drugs alone. In contrast, the effects of the combinations of NGF, LL-37, and PG-1 with temozolomide were less cytotoxic than the effects of the chemotherapy drug alone. Furthermore, the combinations of LL-37, PG-1, and NGF with temozolomide have less cytotoxic effects in comparison with those of temozolomide in C6 glioma cells [55]. In this study, we revealed that the combination of PG-1 with etoposide indicates a synergy cytotoxic effect in glioma U251 cells. Furthermore, the combination of PG-1 with doxorubicin has an additive cytotoxic effect in glioma U251 cells. Other combinations showed antagonism in these cells.

Porcine protegrin-1 (PG-1) is a potent AMP with broad-spectrum antibacterial and antiviral activity. Amphipathic β -sheets are used to penetrate and form pores in the membrane by several toxins that have been designated [75–79]. Several studies have shown

multiple individual mechanisms or a combination of mechanisms of AMPs cytotoxic activities that cause cell lysis, leading to necrosis or programmed cell death [80–82]. Soundrarajan et al. estimated PG-1 cytotoxicity to embryonic fibroblasts, retinal cells, embryonic kidney cells, neuroblastoma cells, alveolar macrophage cells, and neutrophils [83]. The study demonstrated that the cellular toxicity of PG-1 depends on its conformational change when binding with various types of cells [83].

Moreover, the current study revealed that the combination of PG-1 and etoposide had a synergistic effect on the apoptosis of U251 glioma cells. The caspase-3 activation analysis demonstrated that the caspase-3 level was not significantly ($p > 0.05$) increased in the U251 cells following PG-1 + etoposide treatment compared with that in the untreated cells, suggesting that the combination of PG-1 and etoposide may induce caspase-independent apoptosis in U251 cells. Ren et al. revealed that LL-37 induces caspase-independent apoptosis in human colon cancer cells through the initiation of the Gi-coupled GPCR-p53-Bcl-2/Bax/Bak-AIF/EndoG pathway [72]. These data support further research to synthesize the LL-37 peptide as a potential inducer of caspase-independent apoptosis.

5. Conclusions

Our results showed that NGF, LL-37, and PG-1 were significantly cytotoxic to U251 GBM cells compared to chemotherapy. NGF, LL-37, and PG-1 represent promising drug candidates to offer to patients with GBM. Furthermore, the synergistic efficacy of the combined protocol using PG-1 and etoposide might open new horizons in GBM therapy for its ability to eliminate the typical constraints associated with conventional treatment modalities. However, this current concept should be considered as preliminary, and the results need to be confirmed in future studies.

Author Contributions: All authors contributed to the study conception and design. O.S. supervised; A.C., E.G., I.K. and A.K. conducted the experiments; D.A. and A.T. performed the statistical analysis; A.C. and E.G. wrote, reviewed, and edited the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: The project is funded by the Ministry of Education and Science of the Russian Federation, Agreement №075-15-2022-302 (20 April 2022).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: All source data supporting the findings of this manuscript are available from the corresponding authors upon request.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. GBD 2016 Brain and Other CNS Cancer Collaborators. Global, regional, and national burden of brain and other CNS cancer, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. *Lancet Neurol.* **2019**, *18*, 376–393. [[CrossRef](#)]
2. Ferlay, J.; Ervik, M.; Lam, F.; Colombet, M.; Mery, L.; Piñeros, M.; Znaor, A.; Soerjomataram, I.; Bray, F. Global cancer observatory: Cancer today. *Lyon Fr. Int. Agency Res. Cancer* **2018**, *3*, 2019.
3. Nabors, L.B.; Portnow, J.; Ahluwalia, M.; Baehring, J.; Brem, H.; Brem, S.; Butowski, N.; Campian, J.L.; Clark, S.W.; Fabiano, A.J.; et al. Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. *J. Natl. Compr. Cancer Netw. JNCCN* **2020**, *18*, 1537–1570. [[CrossRef](#)]
4. Stupp, R.; Taillibert, S.; Kanner, A.; Read, W.; Steinberg, D.; Lhermitte, B.; Toms, S.; Idbaih, A.; Ahluwalia, M.S.; Fink, K.; et al. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial. *JAMA* **2017**, *318*, 2306–2316. [[CrossRef](#)] [[PubMed](#)]
5. Chen, X.; Zhang, M.; Gan, H.; Wang, H.; Lee, J.H.; Fang, D.; Kitange, G.J.; He, L.; Hu, Z.; Parney, I.F.; et al. A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma. *Nat. Commun.* **2018**, *9*, 2949. [[CrossRef](#)] [[PubMed](#)]
6. Loeffler, J.S.; Alexander, E., 3rd; Hochberg, F.H.; Wen, P.Y.; Morris, J.H.; Schoene, W.C.; Siddon, R.L.; Morse, R.H.; Black, P.M. Clinical patterns of failure following stereotactic interstitial irradiation for malignant gliomas. *Int. J. Radiat. Oncol. Biol. Phys.* **1990**, *19*, 1455–1462. [[CrossRef](#)]

7. Saunders, N.A.; Simpson, F.; Thompson, E.W.; Hill, M.M.; Endo-Munoz, L.; Leggatt, G.; Minchin, R.F.; Guminski, A. Role of intratumoural heterogeneity in cancer drug resistance: Molecular and clinical perspectives. *EMBO Mol. Med.* **2012**, *4*, 675–684. [[CrossRef](#)]
8. Furnari, F.B.; Cloughesy, T.F.; Cavenee, W.K.; Mischel, P.S. Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma. *Nat. Rev. Cancer* **2015**, *15*, 302–310. [[CrossRef](#)]
9. Qazi, M.A.; Vora, P.; Venugopal, C.; Sidhu, S.S.; Moffat, J.; Swanton, C.; Singh, S.K. Intratumoral heterogeneity: Pathways to treatment resistance and relapse in human glioblastoma. *Ann. Oncol. Off. J. Eur. Soc. Med. Oncol.* **2017**, *28*, 1448–1456. [[CrossRef](#)]
10. Gupta, S.K.; Kizilbash, S.H.; Daniels, D.J.; Sarkaria, J.N. Editorial: Targeted Therapies for Glioblastoma: A Critical Appraisal. *Front. Oncol.* **2019**, *9*, 1216. [[CrossRef](#)]
11. Di Tacchio, M.; Macas, J.; Weissenberger, J.; Sommer, K.; Bähr, O.; Steinbach, J.P.; Senft, C.; Seifert, V.; Glas, M.; Herrlinger, U.; et al. Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGF. *Cancer Immunol. Res.* **2019**, *7*, 1910–1927. [[CrossRef](#)] [[PubMed](#)]
12. Polivka, J.; Polivka, J.; Holubec, L.; Kubikova, T.; Priban, V.; Hes, O.; Pivovarcikova, K.; Treskova, I. Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme. *Anticancer Res.* **2017**, *37*, 21–33. [[CrossRef](#)] [[PubMed](#)]
13. Balandin, S.V.; Emelianova, A.A.; Kalashnikova, M.B.; Kokryakov, V.N.; Shamova, O.V.; Ovchinnikova, T.V. Molecular Mechanisms of Anticancer Action of Natural Antimicrobial Peptides. *Bioorganic Chem.* **2016**, *42*, 633–648.
14. CIBA Foundation Symposium. *Growth Factors in Biology and Medicine*; Evered, D., Nugent, J., Whelan, J., Eds.; John Wiley & Sons: Hoboken, NJ, USA, 2009; ISBN 0470718676/9780470718674.
15. Apfel, S.C.; Arezzo, J.C.; Brownlee, M.; Federoff, H.; Kessler, J.A. Nerve growth factor administration protects against experimental diabetic sensory neuropathy. *Brain Res.* **1994**, *634*, 7–12. [[CrossRef](#)]
16. Aloe, L.; Rocco, M.L.; Balzamino, B.O.; Micera, A. Nerve growth factor: Role in growth, differentiation and controlling cancer cell development. *J. Exp. Clin. Cancer Res. CR* **2016**, *35*, 116. [[CrossRef](#)]
17. Verge, V.M.; Merlio, J.P.; Grondin, J.; Ernfors, P.; Persson, H.; Riopelle, R.J.; Hökfelt, T.; Richardson, P.M. Colocalization of NGF binding sites, trk mRNA, and low-affinity NGF receptor mRNA in primary sensory neurons: Responses to injury and infusion of NGF. *J. Neurosci. Off. J. Soc. Neurosci.* **1992**, *12*, 4011–4022. [[CrossRef](#)]
18. Chiaretti, A.; Antonelli, A.; Genovese, O.; Fernandez, E.; Di Giuda, D.; Mariotti, P.; Riccardi, R. Intraventricular nerve growth factor infusion improves cerebral blood flow and stimulates doublecortin expression in two infants with hypoxic-ischemic brain injury. *Neurol. Res.* **2008**, *30*, 223–228. [[CrossRef](#)]
19. Goretzki, P.E.; Wahl, R.A.; Becker, R.; Koller, C.; Branscheid, D.; Grussendorf, M.; Roeher, H.D. Nerve growth factor (NGF) sensitizes human medullary thyroid carcinoma (hMTC) cells for cytostatic therapy in vitro. *Surgery* **1987**, *102*, 1035–1042.
20. Rakowicz-Szulczyńska, E.M.; Herlyn, M.; Koprowski, H. Nerve growth factor receptors in chromatin of melanoma cells, proliferating melanocytes, and colorectal carcinoma cells in vitro. *Cancer Res.* **1988**, *48 Pt 1*, 7200–7206.
21. Rakowicz-Szulczynska, E.M.; Reddy, U.; Vorbodt, A.; Herlyn, D.; Koprowski, H. Chromatin and cell surface receptors mediate melanoma cell growth response to nerve growth factor. *Mol. Carcinog.* **1991**, *4*, 388–396. [[CrossRef](#)]
22. Revoltella, R.P.; Butler, R.H. Nerve growth factor may stimulate either division or differentiation of cloned C1300 neuroblastoma cells in serum-free cultures. *J. Cell. Physiol.* **1980**, *104*, 27–33. [[CrossRef](#)] [[PubMed](#)]
23. Zhang, Z.; Yang, Y.; Gong, A.; Wang, C.; Liang, Y.; Chenet, Y. Localization of NGF and TrkA at mitotic apparatus in human glioma cell line U251. *Biochem. Biophys. Res. Commun.* **2005**, *337*, 68–74. [[CrossRef](#)] [[PubMed](#)]
24. Zhu, Z.W.; Friess, H.; Wang, L.; Di Mola, F.F.; Zimmermann, A.; Büchler, M.W. Down-regulation of nerve growth factor in poorly differentiated and advanced human esophageal cancer. *Anticancer Res.* **2000**, *20*, 125–132. [[PubMed](#)]
25. Chiaretti, A.; Falsini, B.; Servidei, S.; Marangoni, D.; Pierri, F.; Riccardi, R. Nerve growth factor eye drop administration improves visual function in a patient with optic glioma. *Neurorehabilit. Neural Repair* **2011**, *25*, 386–390. [[CrossRef](#)]
26. Falsini, B.; Chiaretti, A.; Barone, G.; Piccardi, M.; Pierri, F.; Colosimo, C.; Lazzareschi, I.; Ruggiero, A.; Parisi, V.; Fadda, A.; et al. Topical nerve growth factor as a visual rescue strategy in pediatric optic gliomas: A pilot study including electrophysiology. *Neurorehabilit. Neural Repair* **2011**, *25*, 512–520. [[CrossRef](#)]
27. Falsini, B.; Chiaretti, A.; Rizzo, D.; Piccardi, M.; Ruggiero, A.; Manni, L.; Soligo, M.; Dickmann, A.; Federici, M.; Salerni, A.; et al. Nerve growth factor improves visual loss in childhood optic gliomas: A randomized, double-blind, phase II clinical trial. *Brain A J. Neurol.* **2016**, *139 Pt 2*, 404–414. [[CrossRef](#)]
28. Kimura, S.; Yoshino, A.; Katayama, Y.; Watanabe, T.; Fukushima, T. Growth control of C6 glioma in vivo by nerve growth factor. *J. Neuro-Oncol.* **2002**, *59*, 199–205. [[CrossRef](#)]
29. Zhao, X.; Wu, H.; Lu, H.; Li, G.; Huang, Q. LAMP: A Database Linking Antimicrobial Peptides. *PLoS ONE* **2013**, *8*, e66557. [[CrossRef](#)]
30. Do, N.; Weindl, G.; Grohmann, L.; Salwiczek, M.; Koksche, B.; Kortling, H.C.; Schäfer-Kortling, M. Cationic membrane-active peptides-anticancer and antifungal activity as well as penetration into human skin. *Exp. Dermatol.* **2014**, *23*, 326–331. [[CrossRef](#)]
31. Pushpanathan, M.; Gunasekaran, P.; Rajendhran, J. Antimicrobial peptides: Versatile biological properties. *Int. J. Pept.* **2013**, *2013*, 675391. [[CrossRef](#)]

32. Hoskin, D.W.; Ramamoorthy, A. Studies on anticancer activities of antimicrobial peptides. *Biochim. Et Biophys. Acta* **2008**, *1778*, 357–375. [CrossRef]
33. Mader, J.S.; Hoskin, D.W. Cationic antimicrobial peptides as novel cytotoxic agents for cancer treatment. *Expert Opin. Investig. Drugs* **2006**, *15*, 933–946. [CrossRef] [PubMed]
34. Deslouches, B.; Steckbeck, J.D.; Craigo, J.K.; Doi, Y.; Burns, J.L.; Montelaro, R.C. Engineered cationic antimicrobial peptides to overcome multidrug resistance by ESKAPE pathogens. *Antimicrob. Agents Chemother.* **2015**, *59*, 1329–1333. [CrossRef] [PubMed]
35. Steckbeck, J.D.; Deslouches, B.; Montelaro, R.C. Antimicrobial peptides: New drugs for bad bugs? *Expert Opin. Biol. Ther.* **2014**, *14*, 11–14. [CrossRef] [PubMed]
36. Deslouches, B.; Steckbeck, J.D.; Craigo, J.K.; Doi, Y.; Mietzner, T.A.; Montelaro, R.C. Rational design of engineered cationic antimicrobial peptides consisting exclusively of arginine and tryptophan, and their activity against multidrug-resistant pathogens. *Antimicrob. Agents Chemother.* **2013**, *57*, 2511–2521. [CrossRef] [PubMed]
37. Scocchi, M.; Mardirossian, M.; Runti, G.; Benincasa, M. Non-Membrane Permeabilizing Modes of Action of Antimicrobial Peptides on Bacteria. *Curr. Top. Med. Chem.* **2016**, *16*, 76–88. [CrossRef]
38. Lei, J.; Sun, L.; Huang, S.; Zhu, C.; Li, P.; He, J.; Mackey, V.; Coy, D.H.; He, Q. The antimicrobial peptides and their potential clinical applications. *Am. J. Transl. Res.* **2019**, *11*, 3919–3931.
39. Gkeka, P.; Sarkisov, L. Interactions of phospholipid bilayers with several classes of amphiphilic alpha-helical peptides: Insights from coarse-grained molecular dynamics simulations. *J. Phys. Chem. B* **2010**, *114*, 826–839. [CrossRef]
40. Wang, L.; Dong, C.; Li, X.; Han, W.; Su, X. Anticancer potential of bioactive peptides from animal sources (Review). *Oncol. Rep.* **2017**, *38*, 637–651. [CrossRef]
41. Imamovic, L.; Sommer, M.O. Use of collateral sensitivity networks to design drug cycling protocols that avoid resistance development. *Sci. Transl. Med.* **2013**, *5*, 204ra132. [CrossRef]
42. Cokol, M.; Chua, H.N.; Tasan, M.; Mutlu, B.; Weinstein, Z.B.; Suzuki, Y.; Nergiz, M.E.; Costanzo, M.; Baryshnikova, A.; Giaever, G.; et al. Systematic exploration of synergistic drug pairs. *Mol. Syst. Biol.* **2011**, *7*, 544. [CrossRef] [PubMed]
43. Freshney, R.I. *Animal Cell Culture: A Practical Approach*, 3rd ed.; Oxford University Press: London, UK, 2000.
44. Zhang, S.; Xie, R.; Wan, F.; Ye, F.; Guo, D.; Lei, T. Identification of U251 glioma stem cells and their heterogeneous stem-like phenotypes. *Oncol. Lett.* **2013**, *6*, 1649–1655. [CrossRef] [PubMed]
45. Florento, L.; Matias, R.; Tuaño, E.; Santiago, K.; Dela Cruz, F.; Tuazon, A. Comparison of Cytotoxic Activity of Anticancer Drugs against Various Human Tumor Cell Lines Using In Vitro Cell-Based Approach. *Int. J. Biomed. Sci. IJBS* **2012**, *8*, 76–80. [CrossRef]
46. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. *J. Immunol. Methods* **1983**, *65*, 55–63. [CrossRef]
47. Mohamadi, N.; Kazemi, S.M.; Mohammadian, M.; Milani, A.T.; Moradi, Y.; Yasemi, M.; Ebrahimifar, M.; Tabrizi, M.M.; Shahmabadi, H.E.; Khiyavi, A.A. Toxicity of Cisplatin-Loaded Poly Butyl Cyanoacrylate Nanoparticles in a Brain Cancer Cell Line: Anionic Polymerization Results. *Asian Pac. J. Cancer Prev. APJCP* **2017**, *18*, 629–632.
48. Svirnovsky, A.I. Methodological studies of drug sensitivity of leukemic cells. *Probl. Health Ecol.* **2011**, *3*, 89–91.
49. Chou, T.C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. *Pharmacol. Rev.* **2006**, *58*, 621–681. [CrossRef]
50. Mindukshev, I.; Kudryavtsev, I.; Serebriakova, M.; Trulioff, A.; Gambaryan, S.; Sudnitsyna, J.; Khmelevskoy, D.; Voitenko, N.; Avdonin, P.; Jenkins, R.; et al. Flow Cytometry and Light Scattering Technique in Evaluation of Nutraceuticals. In *Nutraceuticals*; Elsevier: Amsterdam, The Netherlands, 2016; pp. 319–332.
51. Dubashynskaya, N.V.; Golovkin, A.S.; Kudryavtsev, I.V.; Prikhodko, S.S.; Trulioff, A.S.; Bokaty, A.N.; Poshina, D.N.; Raik, S.V.; Skorik, Y.A. Mucoadhesive cholesterol-chitosan self-assembled particles for topical ocular delivery of dexamethasone. *Int. J. Biol. Macromol.* **2020**, *158*, 811–818. [CrossRef]
52. Caspase 3 Assay Kit, Colorimetric: Technical Bulletin (2004) Sigma-Aldrich, Inc 4 p. Available online: <https://www.abcam.com/products/assay-kits/caspase-3-assay-kit-colorimetric-ab39401.html> (accessed on 29 October 2023).
53. van Belle, G.; Fisher, L.D.; Heagerty, P.J.; Lumley, T. *Biostatistics: A Methodology for the Health Sciences*; Fisher, L.D., van Belle, G., Eds.; John Wiley and Sons Inc.: Hoboken, NJ, USA, 2004.
54. Voronina, T.A.; Guzeevatykh, L.S.; Mironov, A.N. *Guidelines for Conducting Preclinical Studies of Drugs*; Mulyar, A.G., Chichenkov, O.N., Eds.; Grif and K: Moscow, Russia, 2012.
55. Chernov, A.N.; Tsapieva, A.; Alaverdian, D.A.; Filatenkova, T.A.; Galimova, E.S.; Suvorova, M.; Shamova, O.V.; Suvorov, A.N. In vitro evaluation of the cytotoxic effect of *Streptococcus pyogenes* strains, protegrin PG-1, cathelicidin LL-37, nerve growth factor and chemotherapy on the C6 glioma cell line. *Molecules* **2022**, *27*, 569. [CrossRef]
56. Chernov, A.N.; Filatenkova, T.A.; Glushakov, R.I.; Buntovskaya, A.S.; Alaverdian, D.A.; Tsapieva, A.N.; Kim, A.V.; Fedorov, E.V.; Skliar, S.S.; Matsko, M.V.; et al. Anticancer effect of cathelicidin LL-37, protegrin PG-1, nerve growth factor NGF, and temozolomide: Impact on the mitochondrial metabolism, clonogenic potential, and migration of human U251 glioma cells. *Molecules* **2022**, *27*, 4988. [CrossRef]
57. Giraud, S.; Loum, E.; Bessette, B.; Mathonnet, M.; Lalloué, F. P75 neurotrophin receptor is sequestered in the Golgi apparatus of the U-87 MG human glioblastoma cell line. *Int. J. Oncol.* **2011**, *38*, 391–399. [PubMed]

58. Oelmann, E.; Sreter, L.; Schuller, I.; Serve, H.; Koenigsmann, M.; Wiedenmann, B.; Oberberg, D.; Reufi, B.; Thiel, E.; Berdel, W.E. Nerve growth factor stimulates clonal growth of human lung cancer cell lines and a human glioblastoma cell line expressing high-affinity nerve growth factor binding sites involving tyrosine kinase signaling. *Cancer Res.* **1995**, *55*, 2212–2219. [[PubMed](#)]
59. Singer, H.S.; Hansen, B.; Martinie, D.; Karp, C.L. Mitogenesis in glioblastoma multiforme cell lines: A role for NGF and its TrkA receptors. *J. Neuro-Oncol.* **1999**, *45*, 1–8. [[CrossRef](#)] [[PubMed](#)]
60. Liu, T.T.; Wang, H.; Wang, F.J.; Xi, Y.F.; Chen, L.H. Expression of nerve growth factor and brain-derived neurotrophic factor in astrocytomas. *Oncol. Lett.* **2018**, *15*, 533–537. [[CrossRef](#)]
61. Yang, Y.; Peng, H.; Chen, C.-B.; Yu, H. Expression and biological significance of nerve growth factor and its receptor in human glioma cell line U251. *Chin. J. Clin. Rehabil.* **2006**, *10*, 94–96.
62. Johnston, A.L.; Lun, X.; Rahn, J.J.; Liacini, A.; Wang, L.; Hamilton, M.G.; Parney, I.F.; Hempstead, B.L.; Robbins, S.M.; Forsyth, P.A.; et al. The p75 neurotrophin receptor is a central regulator of glioma invasion. *PLoS Biol.* **2007**, *5*, e212. [[CrossRef](#)]
63. Hempstead, B.L.; Martin-Zanca, D.; Kaplan, D.R.; Parada, L.F.; Chao, M.V. High-affinity NGF binding requires coexpression of the trk proto-oncogene and the low-affinity NGF receptor. *Nature* **1991**, *350*, 678–683. [[CrossRef](#)]
64. Piktet, E.; Niemirowicz, K.; Wnorowska, U.; Wątek, M.; Wollny, T.; Głuszek, K.; Gózdź, S.; Levental, I.; Bucki, R. The Role of Cathelicidin LL-37 in Cancer Development. *Arch. Immunol. Et Ther. Exp.* **2016**, *64*, 33–46. [[CrossRef](#)]
65. Chen, X.; Zou, X.; Qi, G.; Tang, Y.; Guo, Y.; Si, J.; Liang, L. Roles and Mechanisms of Human Cathelicidin LL-37 in Cancer. *Cell. Physiol. Biochem. Int. J. Exp. Cell. Physiol. Biochem. Pharmacol.* **2018**, *47*, 1060–1073. [[CrossRef](#)]
66. An, L.L.; Ma, X.-T.; Yang, Y.-H.; Lin, Y.-M.; Song, Y.-H.; Wu, K.-F. Marked reduction of LL-37/hCAP-18, an antimicrobial peptide, in patients with acute myeloid leukemia. *Int. J. Hematol.* **2005**, *81*, 45–47. [[CrossRef](#)]
67. Yang, Y.H.; Zheng, G.-G.; Li, G.; Zhang, B.; Song, Y.-H.; Wu, K.-F. Expression of LL-37/hCAP-18 gene in human leukemia cells. *Leuk. Res.* **2003**, *27*, 947–950. [[CrossRef](#)] [[PubMed](#)]
68. Wu, W.K.; Yiu Sung, J.J.; To, K.F.; Yu, L.; Li, H.T.; Li, Z.J.; Chu, K.M.; Yu, J.; Cho, C.H. The host defense peptide LL-37 activates the tumor-suppressing bone morphogenetic protein signaling via inhibition of proteasome in gastric cancer cells. *J. Cell. Physiol.* **2010**, *223*, 178–186. [[CrossRef](#)] [[PubMed](#)]
69. Heilborn, J.D.; Nilsson, M.F.; Chamorro Jimenez, C.I.; Sandstedt, B.; Borregaard, N.; Tham, E.; Sørensen, O.E.; Weber, G.; Ståhle, M. Antimicrobial protein hCAP18/LL-37 is highly expressed in breast cancer and is a putative growth factor for epithelial cells. *Int. J. Cancer* **2005**, *114*, 713–719. [[CrossRef](#)] [[PubMed](#)]
70. Coffelt, S.B.; Waterman, R.S.; Florez, L.; Höner zu Bentrup, K.; Zvezdaryk, K.J.; Tomchuck, S.L.; LaMarca, H.L.; Danka, E.S.; Morris, C.A.; Scandurro, A.B. Ovarian cancers overexpress the antimicrobial protein hCAP-18 and its derivative LL-37 increases ovarian cancer cell proliferation and invasion. *Int. J. Cancer* **2008**, *122*, 1030–1039. [[CrossRef](#)]
71. von Haussen, J.; Koczulla, R.; Shaykhiev, R.; Herr, C.; Pinkenburg, O.; Reimer, D.; Wiewrodt, R.; Biesterfeld, S.; Aigner, A.; Czubayko, F.; et al. The host defence peptide LL-37/hCAP-18 is a growth factor for lung cancer cells. *Lung Cancer* **2008**, *59*, 12–23. [[CrossRef](#)]
72. Ren, S.X.; Cheng, A.S.; To, K.F.; Tong, J.H.; Li, M.S.; Shen, J.; Wong, C.C.; Zhang, L.; Chan, R.L.; Wang, X.J.; et al. Host immune defense peptide LL-37 activates caspase-independent apoptosis and suppresses colon cancer. *Cancer Res.* **2012**, *72*, 6512–6523. [[CrossRef](#)]
73. Colle, J.H.; Périchon, B.; Garcia, A. Antitumor and antibacterial properties of virally encoded cationic sequences. *Biol. Targets Ther.* **2019**, *13*, 117–126. [[CrossRef](#)]
74. Coelho Neto, G.T.; de Lima, T.M.; Barbeiro, H.V.; Chammas, R.; César Machado, M.C.; da Silva, F.P. Cathelicidin LL-37 Promotes or Inhibits Cancer Cell Stemness Depending on the Tumor Origin. *Oncomedicine* **2016**, *1*, 14–17. [[CrossRef](#)]
75. Bolintineanu, D.; Hazrati, E.; Davis, H.T.; Lehrer, R.I.; Kaznessis, Y.N. Antimicrobial mechanism of pore-forming protegrin peptides: 100 pores to kill *E. coli*. *Peptides* **2010**, *31*, 1–8. [[CrossRef](#)]
76. Edwards, I.A.; Elliott, A.G.; Kavanagh, A.M.; Zuegg, J.; Blaskovich, M.A.T.; Cooper, M.A. Contribution of Amphipathicity and Hydrophobicity to the Antimicrobial Activity and Cytotoxicity of β -Hairpin Peptides. *ACS Infect. Dis.* **2016**, *2*, 442–450. [[CrossRef](#)]
77. Drin, G.; Tamsamani, J. Translocation of protegrin I through phospholipid membranes: Role of peptide folding. *Biochim. Et Biophys. Acta* **2002**, *1559*, 160–170. [[CrossRef](#)]
78. Lipkin, R.B.; Lazaridis, T. Implicit Membrane Investigation of the Stability of Antimicrobial Peptide β -Barrels and Arcs. *J. Membr. Biol.* **2015**, *248*, 469–486. [[CrossRef](#)]
79. Lam, K.L.; Wang, H.; Siaw, T.A.; Chapman, M.R.; Waring, A.J.; Kindt, J.T.; Lee, K.Y. Mechanism of structural transformations induced by antimicrobial peptides in lipid membranes. *Biochim. Et Biophys. Acta* **2012**, *1818*, 194–204. [[CrossRef](#)]
80. Paredes-Gamero, E.J.; Martins, M.N.; Cappabianco, F.A.; Ide, J.S.; Miranda, A. Characterization of dual effects induced by antimicrobial peptides: Regulated cell death or membrane disruption. *Biochim. Et Biophys. Acta* **2012**, *1820*, 1062–1072. [[CrossRef](#)]
81. Soletti, R.C.; del Barrio, L.; Daffre, S.; Miranda, A.; Borges, H.L.; Moura-Neto, V.; Lopez, M.G.; Gabilan, N.H. Peptide gomesin triggers cell death through L-type channel calcium influx, MAPK/ERK, PKC and PI3K signaling and generation of reactive oxygen species. *Chem.-Biol. Interact.* **2010**, *186*, 135–143. [[CrossRef](#)]

82. Cruz-Chamorro, L.; Gwak, J.W.; Kamarajan, P.; Fenno, J.C.; Rickard, A.H.; Kapila, Y.L. In vitro biological activities of magainin alone or in combination with nisin. *Peptides* **2006**, *27*, 1201–1209. [[CrossRef](#)]
83. Soundrarajan, N.; Park, S.; Van Chanh, Q.L.; Cho, H.-S.; Raghunathan, G.; Ahn, B.; Song, H.; Kim, J.-H.; Park, C. Protegrin-1 cytotoxicity towards mammalian cells positively correlates with the magnitude of conformational changes of the unfolded form upon cell interaction. *Sci. Rep.* **2019**, *9*, 11569. [[CrossRef](#)]

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.